Author/Authors :
Tsang، نويسنده , , Jennifer L.Y. and Mendelsohn، نويسنده , , Aurora and Tan، نويسنده , , Mary K.K. and Hackam، نويسنده , , Daniel G. and Leiter، نويسنده , , Lawrence A. and Fitchett، نويسنده , , David and Lin، نويسنده , , Peter J. and Grima، نويسنده , , Etienne and Langer، نويسنده , , Anatoly and Goodman، نويسنده , , Shaun G.، نويسنده ,
Abstract :
Despite clinical trial evidence supporting the use of antiplatelets, angiotensin-converting enzyme inhibitors, and statins for cardiovascular risk reduction in high-risk patients, use of such therapies in real-world outpatients in the prospective Vascular Protection Registry and the Guidelines Oriented Approach to Lipid Lowering Registry was suboptimal (78%, 55%, and 75%, respectively). The most frequent reason physicians cited for nonprescription of statins (33%) was that patients were not high risk enough and/or current guidelines did not support statin use. In conclusion, outpatients at high cardiovascular risk continue to be undertreated as a result of a combination of physician underestimation of cardiovascular risk (knowledge gap) and barriers to implementation of evidence-based therapy (practice gap).
